| abstract |
Provided are novel anti-IL-6 antibodies and new therapies and treatment protocols using anti-IL-6 antibodies, and pharmaceutical formulations containing anti-IL-6 antibodies. The anti-IL-6 antibody is Ab1, its rabbit or humanized form, and its heavy chain, light chain, fragment, variant, and CDR, or intact human IL-6 An antibody or antibody fragment that specifically binds to the same linear or conformational epitope as Ab1 on the polypeptide fragment. [Selection figure] None |